How WHO works to prevent drug use, reduce harm and improve safe access to medicines
Practical Guidance for collaborative interventions
İŞBİRLİĞİ ODAKLI MÜDAHALELERE DAYALI UYGULANABİLİR YAKLAŞIMLAR
World Health Organization (2013)
Kırmızı Şemsiye Cinsel Sağlık ve İnsan Hakları Derneği (2017)
Guidelines
Key Populations
Par ses propriétés thérapeutiques, le médicament permet aux professionnels de santé
ainsi quaux pouvoirs publics dassurer la santé des populations. De ce fait, sa disponibilité et
son efficacité sont essentielles et sont le résultat dun circuit complexe (de sa fabrication... à sa
destruction en passant par sa distribution).
Laccessibilité au médicament est un élément déterminant de toute politique de santé.
Elle est garantie par la politique pharmaceutique de chaque pays qui vise à rendre le
médicament disponible pour tous, sur lensemble du territoire (accessibilité géographique), à
tout moment (accessibilité physique), à un prix abordable (accessibilité financière) et en
garantissant son efficacité et sa qualité (accessibilité qualitative
more
The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable ...results at the national, regional and global levels.
This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years.
more
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
UNAIDS/WHO 2015 | Reference
Product:BDFACSCountTM InstrumentSystemwithFACSCountTM ControlKitandBD FACSCountTM CD4ReagentKit(AbsoluteandPercentageCD4+Counts)
Number: PQDx 0133-045-00
0133-045-00 WHO
PQDx PR
June/2016, version 2.0
PQDx 0197-045-00 WHO
PQDx PR
March /2016, version 2.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
PQDx 0159-055-00
WHO PQ Public Report
February/2017, version 5.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
Information Note
Advice for countries using or planning
to introduce dual HIV/syphilis RDT in antenatal services and other testing sites.
WHO/RHR/17.01
Examen du rôle de la société civile dans le plaidoyer et le lobbying en faveur de l'application de la politique de santé au Kenya
African Population Studies Vol 25, 1 (Supplement) 2011
http://aps.journals.ac.za